This has promising implications for the application of a LOTUS-targeting therapeutic strategy to ALS patients with TDP-43 aggregation, a context in which ataxin-2 reduction may have important therapeutic effects. Here, ATXN2 is linked to amyotrophic lateral sclerosis.